This HTML5 document contains 17 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

PrefixNamespace IRI
n10http://www.wikidata.org/prop/direct/
dcthttp://purl.org/dc/terms/
n2http://taxref.mnhn.fr/lod/bib/
foafhttp://xmlns.com/foaf/0.1/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
taxrefhttp://taxref.mnhn.fr/lod/
bibohttp://purl.org/ontology/bibo/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7https://www.mdpi.com/2079-6382/12/6/1020/
xsdhhttp://www.w3.org/2001/XMLSchema#
Subject Item
n2:434841
rdf:type
schema:CreativeWork bibo:Document
rdfs:label
Rybak <i>et al.</i> (2023)
rdfs:isDefinedBy
taxref:taxref-ld
schema:datePublished
2023-01-01
dct:title
Rybak <i>et al.</i> (2023)
foaf:page
n7:pdf
schema:identifier
_:vb70019836
dct:abstract
<jats:p>Epidemiological surveillance of nasopharyngeal pneumococcal carriage is important for monitoring serotype distribution and antibiotic resistance, particularly before and after the implementation of pneumococcal conjugate vaccines (PCVs). With a prospective surveillance study in France, we aimed to analyze the dynamics of pneumococcal carriage, antibiotic susceptibility and serotype distribution in children aged 6 to 24 months who had acute otitis media between 2001 and 2022 with a focus on the late PCV13 period from May 2014 to July 2022. Trends were analyzed with segmented linear regression with autoregressive error. For the 17,136 children enrolled, overall pneumococcal carriage was stable during the study. During the late PCV13 period, the five most frequent serotypes were all non-PCV13 serotypes: 15B/C (14.3%), 23B (11.0%), 11A (9.6%), 15A (7.4%) and 35B (6.5%). During the same period, we observed a rebound of penicillin non-susceptibility (+0.15% per month, 95% confidence interval, +0.08 to 0.22, p &lt; 0.001). Five serotypes accounted for 64.4% of the penicillin non-susceptible strains: 11A (17.5%), 35B (14.9%), 15A (13.9%), 15B/C (9.9%) and 19F (8.2%); non-PCV13/PCV15 accounted for &lt;1%, and non-PCV15/PCV20 accounted for 28%. The next generation PCVs, particularly PCV20, may disrupt nasopharyngeal carriage and contribute to decreasing the rate of antibiotic resistance among pneumococci.</jats:p>
bibo:abstract
<jats:p>Epidemiological surveillance of nasopharyngeal pneumococcal carriage is important for monitoring serotype distribution and antibiotic resistance, particularly before and after the implementation of pneumococcal conjugate vaccines (PCVs). With a prospective surveillance study in France, we aimed to analyze the dynamics of pneumococcal carriage, antibiotic susceptibility and serotype distribution in children aged 6 to 24 months who had acute otitis media between 2001 and 2022 with a focus on the late PCV13 period from May 2014 to July 2022. Trends were analyzed with segmented linear regression with autoregressive error. For the 17,136 children enrolled, overall pneumococcal carriage was stable during the study. During the late PCV13 period, the five most frequent serotypes were all non-PCV13 serotypes: 15B/C (14.3%), 23B (11.0%), 11A (9.6%), 15A (7.4%) and 35B (6.5%). During the same period, we observed a rebound of penicillin non-susceptibility (+0.15% per month, 95% confidence interval, +0.08 to 0.22, p &lt; 0.001). Five serotypes accounted for 64.4% of the penicillin non-susceptible strains: 11A (17.5%), 35B (14.9%), 15A (13.9%), 15B/C (9.9%) and 19F (8.2%); non-PCV13/PCV15 accounted for &lt;1%, and non-PCV15/PCV20 accounted for 28%. The next generation PCVs, particularly PCV20, may disrupt nasopharyngeal carriage and contribute to decreasing the rate of antibiotic resistance among pneumococci.</jats:p>
dct:issued
2023-01-01
dct:bibliographicCitation
Rybak, A., Levy, C., Ouldali, N., Bonacorsi, S., Béchet, S., Delobbe, J., Batard, C., Donikian, I., Goldrey, M., Assouline, J., Cohen, R. &amp; Varon, E. 2023. Dynamics of Antibiotic Resistance of Streptococcus pneumoniae in France: A Pediatric Prospective Nasopharyngeal Carriage Study from 2001 to 2022. <em>Antibiotics</em>, 12(6): 1020.
bibo:doi
10.3390/antibiotics12061020
schema:sameAs
n7:pdf
Subject Item
_:vb70019836
rdf:type
schema:PropertyValue
schema:propertyID
n10:P356
schema:value
10.3390/antibiotics12061020